【摘要】 目的 探讨信迪利单抗联合化疗治疗晚期非小细胞肺癌患者的疗效及对血清肿瘤标志物的影响。方法根据治疗方案的不同将147例晚期非小细胞肺癌患者分为对照组（n=73）和观察组（n=74），对照组患者接受白蛋白紫杉醇+卡铂治疗，观察组患者接受信迪利单抗联合白蛋白紫杉醇+卡铂治疗。比较两组患者的临床疗效、血清肿瘤标志物[癌胚抗原（CEA）、细胞角质蛋白19片段抗原21-1(CYFRA21-1)]、不良反应发生情况及生存情况。结果 观察组患者的总有效率为52.70%，高于对照组患者的35.62%，差异有统计学意义（P﹤0.05）。治疗后，两组患者血清CEA、CYFRA21-1水平均低于本组治疗前，观察组患者血清CEA、CYFRA21-1水平均低于对照组，差异均有统计学意义（P﹤0.05）。两组患者疲劳乏力、血小板减少、消化道反应发生率比较，差异均无统计学意义（P﹥0.05）。随访1年，观察组患者生存34例，1年生存率为45.95%，高于对照组患者的28.77%，差异有统计学意义（P﹤0.05）。结论 信迪利单抗联合白蛋白紫杉醇+卡铂治疗晚期非小细胞肺癌患者，可提高临床疗效，降低血清CEA、CYFRA21-1水平，提高生存率。更多还原

【Abstract】 Objective To explore the efficacy of sintilimab combined with chemotherapy in the treatment of patients with advanced non-small cell lung cancer and its influence on serum tumor markers. Method According to different treatment methods, 147 patients with advanced non-small cell lung cancer were divided into control group(n=73) and observation group(n=74). Patients in the control group received albumin paclitaxel + carboplatin treatment, while the patients in the observation group received sintilimab combined with albumin paclitaxel + carboplatin treatment. The clinical efficacy, serum tumor markers [carcinoembryonic antigen(CEA), cyto-keratin 19 fragment antigen 21-1(CYFRA21-1)],incidence of adverse reactions, and survival status were compared between the two groups. Result The total effective rate in observation group was 52.70%, which was higher than 35.62% in control group, and the difference was statistically significant(P<0.05). After treatment, the levels of serum CEA, CYFRA21-1 in both groups were lower than those before treatment, the levels of serum CEA, CYFRA21-1 in observation group were lower than those in control group, and the differences were statistically significant(P<0.05). There were no statistically significant differences in the incidences of fatigue and weakness, thrombocytopenia, and gastrointestinal reactions between the two groups(P>0.05). After 1-year follow-up, 34 patients in the observation group survived, with 1-year survival rate of 45.95%, which was higher than28.77% in control group, and the difference was statistically significant(P<0.05). Conclusion The sintilimab combined with albumin paclitaxel + carboplatin in the treatment of patients with advanced non-small cell lung cancer can improve clinical efficacy, reduce serum CEA and CYFRA21-1 levels, and improve survival rate.更多还原